BR112022018287A2 - Compostos moduladores de gpr52 - Google Patents

Compostos moduladores de gpr52

Info

Publication number
BR112022018287A2
BR112022018287A2 BR112022018287A BR112022018287A BR112022018287A2 BR 112022018287 A2 BR112022018287 A2 BR 112022018287A2 BR 112022018287 A BR112022018287 A BR 112022018287A BR 112022018287 A BR112022018287 A BR 112022018287A BR 112022018287 A2 BR112022018287 A2 BR 112022018287A2
Authority
BR
Brazil
Prior art keywords
gpr52
modulating compounds
report
compounds
modulating
Prior art date
Application number
BR112022018287A
Other languages
English (en)
Inventor
Joanne Bucknell Sarah
Paul Watson Stephen
Alistair O'brien Michael
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of BR112022018287A2 publication Critical patent/BR112022018287A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)

Abstract

COMPOSTOS MODULADORES DE GPR52. As divulgações neste relatório referem-se a novos compostos da Fórmula (1):(1) e sais dos mesmos, em que X, Y, R1, R2, R3 e R4 são definidos neste relatório, e seu uso no tratamento, prevenção, melhoria, controle ou redução do risco de transtornos associados aos receptores de GPR52.
BR112022018287A 2020-03-13 2021-03-15 Compostos moduladores de gpr52 BR112022018287A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2003668.7A GB202003668D0 (en) 2020-03-13 2020-03-13 GPR52 Modulator compounds
PCT/GB2021/050638 WO2021181122A1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
BR112022018287A2 true BR112022018287A2 (pt) 2022-11-22

Family

ID=70453676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018287A BR112022018287A2 (pt) 2020-03-13 2021-03-15 Compostos moduladores de gpr52

Country Status (14)

Country Link
US (1) US20240254101A1 (pt)
EP (1) EP4117784B1 (pt)
JP (1) JP7492597B2 (pt)
KR (1) KR20220152296A (pt)
CN (1) CN115515681B (pt)
AU (1) AU2021235257A1 (pt)
BR (1) BR112022018287A2 (pt)
CA (1) CA3175429A1 (pt)
DK (1) DK4117784T3 (pt)
FI (1) FI4117784T3 (pt)
GB (1) GB202003668D0 (pt)
IL (1) IL296413A (pt)
MX (1) MX2022011333A (pt)
WO (1) WO2021181122A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240208907A1 (en) * 2021-04-26 2024-06-27 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
WO2024091542A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
WO2024091538A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
JPWO2011078360A1 (ja) 2009-12-24 2013-05-09 武田薬品工業株式会社 アミド化合物
WO2011093352A1 (ja) 2010-01-27 2011-08-04 武田薬品工業株式会社 チアゾール誘導体
ES2784316T3 (es) 2015-04-29 2020-09-24 Arena Pharm Inc 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo
JP7394747B2 (ja) * 2017-09-13 2023-12-08 ノバルティス アーゲー ジフェニル誘導体及びその使用

Also Published As

Publication number Publication date
CN115515681A (zh) 2022-12-23
IL296413A (en) 2022-11-01
WO2021181122A1 (en) 2021-09-16
KR20220152296A (ko) 2022-11-15
FI4117784T3 (fi) 2024-10-10
CN115515681B (zh) 2024-09-03
AU2021235257A1 (en) 2022-10-06
JP7492597B2 (ja) 2024-05-29
MX2022011333A (es) 2022-12-08
CA3175429A1 (en) 2021-09-16
US20240254101A1 (en) 2024-08-01
GB202003668D0 (en) 2020-04-29
EP4117784B1 (en) 2024-08-28
EP4117784A1 (en) 2023-01-18
JP2023519666A (ja) 2023-05-12
DK4117784T3 (da) 2024-10-14

Similar Documents

Publication Publication Date Title
BR112022018287A2 (pt) Compostos moduladores de gpr52
BR112022003375A2 (pt) Compostos de pirazina-amida pesticidamente ativos
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112017021859A2 (pt) ?composto, composição e mistura herbicida e método para o controle do crescimento de vegetação indesejada?
BRPI0616393B8 (pt) compostos heterocíclicos fundidos úteis como moduladores de quinase, composição farmacêutica e usos dos mesmos
BR112017009601A2 (pt) derivados de aminoácidos e seus usos
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
BR0015254A (pt) Derivados de carbamoiloxialquil-azólio substituìdos em n
BR112021017604A2 (pt) Compostos úteis na terapia para hiv
BR112013032391A2 (pt) antagonistas de trpv4
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112023025358A2 (pt) Inibidores de protease como antivirais
BR112022004917A2 (pt) Compostos de amina cíclica pesticidamente ativos
BRPI0512073A (pt) composto, composição farmacêutica, e, uso da mesma
BR112017001439A2 (pt) ?composto, composição e mistura herbicida e métodos de controle do crescimento de vegetação?
BR112022001054A2 (pt) Inibidores enzimáticos
BR112022006906A2 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, medicamento e composição farmacêutica
BR112023025083A2 (pt) Piridinas fundidas para controlar pragas invertebradas
BR0315114A (pt) Compostos, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar (alfa) e/ou ppar (gama)z e/ou utilização dos mesmos
BRPI0417609A (pt) derivados de 3-ciano-quinolina com atividade antiproliferativa
BRPI0408205A (pt) derivado de anilina substituìdo, composição farmacêutica, e, uso de uma composição farmacêutica
MX2021000841A (es) Derivados de quinazolinona sustituidos y su uso como moduladores alostericos positivos de mglur4.
BR0316108A (pt) Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos